Objective
No effective therapy against adrenocortical carcinoma (ACC) is currently available, as is the case for most other solid carcinomas. Recently, new promising therapeutic approaches have arisen, such as immunotherapy based dendritic cell vaccination or targeting the tumour stroma. However, the first clinical trials targeting the tumour stroma with antibodies or small molecules were disappointing. Additionally, it is widely accepted that one treatment modality is not sufficient to cure cancer.
The aim of this study is to combine two promising approaches, immunotherapy and stromal therapy into a novel approach whereby patients are vaccinated against products, which are preferentially over-expressed in the tumour stroma. Thus, we combine the advantages of a classical immunotherapy with targeting the tumour stroma, eliminating some of the inherent limitation of current antistromal strategy, offering an immunological treatment of minimal or no toxicity that should be applicable to almost all solid malignancies. Murine studies will test the hypothesis that an immunization with DC transfected with mRNA encoding tumour stroma antigens (e.g. FAP, MMP14) will inhibit tumour progression. In addition, synergistic effects of an immunotherapy targeting the tumour itself and the tumour stroma will be assessed. A preclinical in-vitro-study will test the capability to stimulate a specific cytotoxic T cell response in humans and will optimise the procedures clinical trials planned in patients with ACC.
The first host is one of the pioneers in the field of dendritic cell based immunotherapy, Prof Gilboa, Duke University, USA. The proposed methods are well established in his laboratory. The second host is Prof Allolio, University of Wuerzburg, Germany. He is one of the leading researchers in the field of adrenocortical carcinoma in Europe. This program will serve as a foundation for establishing a Europe-wide network of investigators to apply these concepts to a broad range of other cancers.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine immunology immunisation
- medical and health sciences clinical medicine oncology skin cancer melanoma
- medical and health sciences clinical medicine oncology breast cancer
- medical and health sciences clinical medicine endocrinology
- medical and health sciences basic medicine immunology immunotherapy
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2002-MOBILITY-6
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
OIF - Marie Curie actions-Outgoing International Fellowships
Coordinator
WUERZBURG
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.